Read the Patent Cliff Before Everyone Else Does: How to Evaluate Biosimilar First-Mover Advantage
In the rapidly evolving landscape of biopharmaceuticals, the so-called “patent cliff” isn’t just a looming threat—it’s a defining moment that can make or break companies. As blockbuster biologics approach patent expiration, the race to capture market s…
